Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.

Date publication

novembre 2019

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LUPORSI Elisabeth

Tous les auteurs :
Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E, Espié M, Guiu S, D'Hondt V, Dieras V, Sablin MP, Brain E, Neffati S, Pierga JY, Bidard FC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31727113

Résumé

In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.

Mots clés

Circulating tumor cells, HER2, Liquid biopsy, Metastatic breast cancer, Trastuzumab-emtansine

Référence

Breast Cancer Res.. 2019 Nov 14;21(1):121